Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adicet Bio, Inc. (ACET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Adicet uses these filings to report on its allogeneic gamma delta CAR T cell programs in autoimmune diseases and cancer, capital raising transactions, and key corporate actions.
Investors can review Form 8-K current reports in which Adicet describes material events such as preliminary Phase 1 data for ADI-001/prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus, updates on enrollment across additional autoimmune indications, strategic pipeline prioritization and discontinuation of ADI-270, and development plans for the ADI-212 solid tumor program. Other 8-K filings cover registered direct offerings of common stock and pre-funded warrants, Nasdaq bid price notices and market transfers, and workforce reduction decisions.
The company’s proxy materials, such as the definitive proxy statement on Schedule 14A for a special meeting of stockholders, outline proposals including amendments to the certificate of incorporation to effect a reverse stock split within a specified range and potential adjournments to solicit additional proxies. These documents detail how stockholders can vote, participate in virtual meetings, and understand the rationale for capital structure changes.
On Stock Titan, ACET filings are updated in near real time as they appear on EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly identify topics such as clinical data disclosures, financing terms, reverse stock split mechanics, and listing compliance discussions. Users can also locate quarterly and annual reports when filed (Forms 10-Q and 10-K), as well as any Form 4 insider transaction reports, to build a more complete picture of Adicet Bio’s financial condition, governance, and progress in advancing its gamma delta CAR T pipeline.
RA Capital Management, L.P. and affiliated reporting persons reported beneficial ownership of 1,182,624 shares of Adicet Bio, Inc. common stock. The filing states the Fund also holds pre-funded warrants exercisable for up to 1,152,833 additional shares, but a Beneficial Ownership Blocker prevents exercise that would raise ownership above 9.99%. The percentage reported (12.3%) is calculated using 9,596,407 shares outstanding as of March 10, 2026. The filing discloses delegated voting and dispositive authority to RA Capital and includes standard disclaimers regarding beneficial ownership for Section 13(d) purposes.
RA Capital–affiliated entities reported open-market purchases of Adicet Bio common stock. RA Capital Healthcare Fund LP, managed by RA Capital Management, L.P., bought 74,577 shares at $7.04 on February 18, 74,268 shares at $7.21 on February 19, and 74,751 shares at $7.27 on February 20. All shares are held directly by the Fund, with RA Capital and individuals Peter Kolchinsky and Rajeev Shah disclaiming beneficial ownership beyond their pecuniary interests. After the latest trade, the indirect holdings reported for the Fund total 1,182,624 shares, and no derivative securities are listed.
Adicet Bio, Inc. received an initial ownership report from RA Capital–related entities, which are ten percent owners. The filing lists indirect holdings of a Pre-Funded Warrant exercisable into 1,152,833 shares of common stock at an exercise price of $0.0001 per share, plus 959,028 shares of common stock held indirectly.
The Pre-Funded Warrants are exercisable immediately and have no expiration date, but contain a 9.99% beneficial ownership cap that prevents exercises taking the group above that level. RA Capital Management, its general partner, the Fund, and Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership beyond their pecuniary interest.
OrbiMed-affiliated funds reduced their stake in Adicet Bio, Inc. common stock and filed Amendment No. 9 to Schedule 13D. The reporting group, led by OrbiMed Advisors LLC, now may be deemed to beneficially own 844,787 Shares, representing 8.8% of Adicet Bio’s 9,596,407 Shares outstanding as stated in the company’s Form 10-K.
OrbiMed Private Investments V, LP holds 564,147 Shares (5.9%), and OrbiMed Private Investments VI, LP holds 280,640 Shares (2.9%). Other OrbiMed-related vehicles, including OrbiMed Genesis Master Fund, OrbiMed Israel Partners and OrbiMed Israel Partners II, report holding 0 Shares.
The amendment was triggered after open-market sales described in Item 5(c), including April 7–8, 2026 transactions by OrbiMed Israel Partners and OrbiMed Israel Partners II and an April 9, 2025 sale by OrbiMed Genesis at per-share prices in the mid-$6 range.
Adicet Bio shareholder update: Investment entities affiliated with OrbiMed reported open-market sales of a total of 104,658 shares of Adicet Bio common stock on April 7–8, 2026, at prices between about $6.29 and $6.53 per share. The Form 4 shows these OrbiMed-related funds continuing to hold sizable indirect positions, including 564,147 shares, 280,640 shares, and 78,499 shares of Adicet Bio common stock through various limited partnerships.
Adicet Bio, Inc. reported that Chief Financial Officer Brian Nicholas received a grant of stock options covering 43,361 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. According to the vesting terms, 1/48th of the options vest on each monthly anniversary of the grant over forty-eight months, as long as he continues his service relationship with the company. Following this grant, he holds 43,361 stock options directly.
Adicet Bio, Inc. reported that President & CEO Chen Schor received a grant of stock options representing the right to buy 468,555 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036.
This award is compensation-related and not an open-market share purchase or sale. The filing notes that one forty-eighth of the options vest each month over 48 months from the grant date, contingent on Mr. Schor continuing his service with the company.